Cargando…
The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial
RATIONALE: There are widespread histaminergic projections throughout the brain, including hypoglossal nuclei, that modulate pharyngeal muscle tone and respiratory control. Hence, histaminergic stimulation pharmacologically may increase pharyngeal muscle tone and stabilize respiratory control (loop g...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188336/ https://www.ncbi.nlm.nih.gov/pubmed/35698591 http://dx.doi.org/10.2147/NSS.S362205 |
_version_ | 1784725352036171776 |
---|---|
author | Messineo, Ludovico Loffler, Kelly Chiang, Alan Osman, Amal Taranto-Montemurro, Luigi Eckert, Danny J |
author_facet | Messineo, Ludovico Loffler, Kelly Chiang, Alan Osman, Amal Taranto-Montemurro, Luigi Eckert, Danny J |
author_sort | Messineo, Ludovico |
collection | PubMed |
description | RATIONALE: There are widespread histaminergic projections throughout the brain, including hypoglossal nuclei, that modulate pharyngeal muscle tone and respiratory control. Hence, histaminergic stimulation pharmacologically may increase pharyngeal muscle tone and stabilize respiratory control (loop gain) to reduce obstructive sleep apnea (OSA) severity. Antimuscarinics also increase REM pharyngeal muscle tone in rats. Thus, a combination of histaminergic and anti-muscarinic drugs may be a novel target for OSA pharmacotherapy. However, this has not been investigated. Accordingly, we aimed to test the effects of betahistine (Beta), an H3-autoreceptor antagonist which thereby increases histamine levels, in combination with the antimuscarinic oxybutynin (Oxy), on OSA severity, OSA endotypes, polysomnography parameters and next-day sleepiness and alertness. METHODS: Thirteen adults with OSA received either Beta-Oxy (96–5mg) or placebo according to a randomized, crossover, double-blind design, prior to polysomnography. Participants completed the Karolinska Sleep Scale and Leeds Sleep Evaluation Questionnaire and a driving simulation task to quantify next-day sleepiness and alertness. OSA endotypes were estimated through validated algorithms using polysomnography. RESULTS: Compared to placebo, Beta-Oxy increased respiratory control sensitivity (loop gain) (0.52[0.24] vs 0.60[0.34], median [IQR], P = 0.021) without systematically changing OSA severity (34.4±17.2 vs 40.3±27.3 events/h, mean±SD, P = 0.124), sleep efficiency, arousal index or markers of hypoxemia. Beta-Oxy was well tolerated and did not worsen next-day sleepiness/alertness. CONCLUSION: Rather than stabilize breathing during sleep, Beta-Oxy increases loop gain, which is likely to be deleterious for most people with OSA. However, in certain conditions characterized by blunted respiratory control (eg, obesity hypoventilation syndrome), interventions to increase loop gain may be beneficial. |
format | Online Article Text |
id | pubmed-9188336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-91883362022-06-12 The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial Messineo, Ludovico Loffler, Kelly Chiang, Alan Osman, Amal Taranto-Montemurro, Luigi Eckert, Danny J Nat Sci Sleep Original Research RATIONALE: There are widespread histaminergic projections throughout the brain, including hypoglossal nuclei, that modulate pharyngeal muscle tone and respiratory control. Hence, histaminergic stimulation pharmacologically may increase pharyngeal muscle tone and stabilize respiratory control (loop gain) to reduce obstructive sleep apnea (OSA) severity. Antimuscarinics also increase REM pharyngeal muscle tone in rats. Thus, a combination of histaminergic and anti-muscarinic drugs may be a novel target for OSA pharmacotherapy. However, this has not been investigated. Accordingly, we aimed to test the effects of betahistine (Beta), an H3-autoreceptor antagonist which thereby increases histamine levels, in combination with the antimuscarinic oxybutynin (Oxy), on OSA severity, OSA endotypes, polysomnography parameters and next-day sleepiness and alertness. METHODS: Thirteen adults with OSA received either Beta-Oxy (96–5mg) or placebo according to a randomized, crossover, double-blind design, prior to polysomnography. Participants completed the Karolinska Sleep Scale and Leeds Sleep Evaluation Questionnaire and a driving simulation task to quantify next-day sleepiness and alertness. OSA endotypes were estimated through validated algorithms using polysomnography. RESULTS: Compared to placebo, Beta-Oxy increased respiratory control sensitivity (loop gain) (0.52[0.24] vs 0.60[0.34], median [IQR], P = 0.021) without systematically changing OSA severity (34.4±17.2 vs 40.3±27.3 events/h, mean±SD, P = 0.124), sleep efficiency, arousal index or markers of hypoxemia. Beta-Oxy was well tolerated and did not worsen next-day sleepiness/alertness. CONCLUSION: Rather than stabilize breathing during sleep, Beta-Oxy increases loop gain, which is likely to be deleterious for most people with OSA. However, in certain conditions characterized by blunted respiratory control (eg, obesity hypoventilation syndrome), interventions to increase loop gain may be beneficial. Dove 2022-06-07 /pmc/articles/PMC9188336/ /pubmed/35698591 http://dx.doi.org/10.2147/NSS.S362205 Text en © 2022 Messineo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Messineo, Ludovico Loffler, Kelly Chiang, Alan Osman, Amal Taranto-Montemurro, Luigi Eckert, Danny J The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial |
title | The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial |
title_full | The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial |
title_fullStr | The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial |
title_full_unstemmed | The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial |
title_short | The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial |
title_sort | combination of betahistine and oxybutynin increases respiratory control sensitivity (loop gain) in people with obstructive sleep apnea: a randomized, placebo-controlled trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188336/ https://www.ncbi.nlm.nih.gov/pubmed/35698591 http://dx.doi.org/10.2147/NSS.S362205 |
work_keys_str_mv | AT messineoludovico thecombinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT lofflerkelly thecombinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT chiangalan thecombinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT osmanamal thecombinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT tarantomontemurroluigi thecombinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT eckertdannyj thecombinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT messineoludovico combinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT lofflerkelly combinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT chiangalan combinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT osmanamal combinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT tarantomontemurroluigi combinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial AT eckertdannyj combinationofbetahistineandoxybutyninincreasesrespiratorycontrolsensitivityloopgaininpeoplewithobstructivesleepapneaarandomizedplacebocontrolledtrial |